Studies in healthy volunteers show that in single high doses Ativan (lorazepam) has a tranquilizing action on the central nervous system with no appreciable.
Continuous long-term use of product is not recommended. Extension of the treatment period should not take place without reevaluation of the need for continued therapy. Withdrawal symptoms (e.g. Abrupt discontinuation of product should be avoided and a gradual dosage-tapering schedule followed after extended therapy. In general, benzodiazepines should be prescribed for short periods only (e.g. rebound insomnia) can appear following cessation of recommended doses after as little as one week of therapy.
Dosage Range: 1-10mg/day. Increase dose gradually prn; when higher dosage is indicated, increase pm dose before daytime doses. Insomnia Due to Anxiety.
Monitor for respiratory depression, physical/psychological dependence, withdrawal symptoms, tolerance, abuse, suicidal thinking, paradoxical reactions, symptoms of upper GI disease, and emergence/worsening of depression. Monitor elderly/debilitated frequently and addiction-prone individuals carefully. Perform periodic blood counts and LFTs with long-term therapy. Reassess usefulness of drug periodically.
Absorption: Readily absorbed. Distribution: Plasma protein binding (85%); found in breast milk.
Usual Adult Dose for Anxiety. -The daily dosage may vary from 1 to 10 mg per day. -IV: Larger doses as high as 0.05 mg/kg up to a total of 4 mg may be administered.
Availability Rx Prescription only.
Hepatic impairment: Use with caution.
2 to 4 mg orally administered at bedtime Comments : -The dosage should be increased gradually when needed to help avoid adverse effects. Use: Management of insomnia.
CSA Schedule 4 Some potential for abuse.
IM: 0.05 mg/kg up to a maximum of 4 mg IV: 2 mg total, or 0.044 mg/kg, whichever is smaller Comments : -Doses of other injectable central-nervous-system depressant drugs should be reduced. -For optimum effect, intramuscular drug should be administered at least 2 hours before the anticipated operative procedure.
This medicine is to be taken by mouth. Measure the oral liquid with the provided medicine dropper. Dilute each dose with water, juice, soda.
Keep out of the reach of children.
2016 Truven Health Analytics Inc. Information is for End User's use only and may not be sold, redistributed or otherwise used for commercial purposes.
The amount of medicine that you take depends on the strength of the medicine. Also, the number of doses you take each day, the time allowed between doses, and the length of time you take the medicine depend on the medical problem for which you are using the medicine.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic.
Mayo Clinic does not endorse non-Mayo products and services.
Maximum dose of lorazepam for short term, symptomatic treatment is 4 mg per day for severe, disabling anxiety, and 2 mg per day for severe.
Doses of lorazepam above 4 mg per day are not considered appropriate in view of the recommended maximum treatment duration of 4 weeks, which includes a dose-reduction period. Prescribing information, which previously contained posology for up to 10 mg per day for lorazepam (equivalent to 100 mg per day of diazepam), is being updated for relevant products.
Maximum dose of lorazepam for short term, symptomatic treatment is 4 mg per day for severe, disabling anxiety, and 2 mg per day for severe, disabling insomnia.
Article date: October 2007.
Lorazepam is a benzodiazepine anxiolytic; its indications include short-term use in anxiety or insomnia.
Don’t include personal or financial information, eg your National Insurance number or credit card details. Open Government Licence.
EU Referendum On Thursday 23 June there will be a vote on the UK’s membership of the European Union. More information Drug Safety Update.
Advice for healthcare professionals:
Prescribers are reminded of previous advice:
See also British National Formulary for information about lorazepam dosing.
Published: 1 October 2007 Therapeutic area: Psychiatry.
Article citation: Drug Safety Update October 2007; Vol 1, Issue 3: 8.
All content is available under the Open Government Licence v3.0, except where otherwise stated.